We were both pleased to learn that his test in October of 2014 showed a median length of 9,500 base pairs (or up to 25 years improvement) and a reduction to 8.3% critically-shortened telomeres (or a 38% relative reduction):
DISCLAIMER: This website is for educational purposes only and is not for advertising. Telomerase activators and nanovesicles are not FDA-approved to prevent or treat any disease and anecdotes are not scientific proof of efficacy. All patients were treated in the context of a fully informed and legally-protected patient physician relationship.
Required fields
© 2020 Recharge Biomedical
Exosomes and TA-65 are not FDA-approved to prevent or treat any illness
